Evidence map›Paper›PMID 39835701›Full record

ReviewFuture medicinal chemistry2025

Pharmaceutical technological trends containing flavonoids: a patent review.

Ana Maria Santos Oliveira, Anamaria Mendonça Santos, José Adão Carvalho Nascimento Júnior, Cláudio Carvalho Santana Júnior, João Rafael Lisboa Rego Brito, Jussara Secundo Dos Santos, Saravanan Shanmugam, Paula Dos Passos Menezes, Luiza Abrahão Frank, Mairim Russo Serafini

Abstract readReview
In one paragraph

Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ana Maria Santos OliveiraPostgraduate Program in Pharmaceutical Sciences, Federal University of Sergipe, São Cristóvão, Brazil.ORCID 0000-0002-2853-4149
Anamaria Mendonça SantosPostgraduate Program in Health Sciences, Federal University of Sergipe, Aracaju, Brazil.ORCID 0000-0003-1098-3525
José Adão Carvalho Nascimento JúniorPostgraduate Program in Pharmaceutical Sciences, Federal University of Sergipe, São Cristóvão, Brazil.
Cláudio Carvalho Santana JúniorPostgraduate Program in Health Sciences, Federal University of Sergipe, Aracaju, Brazil.
João Rafael Lisboa Rego BritoDepartment of Pharmacy, Federal University of Sergipe, São Cristóvão, Brazil.
Jussara Secundo Dos SantosPostgraduate Program in Pharmaceutical Sciences, Federal University of Sergipe, São Cristóvão, Brazil.
Saravanan ShanmugamPostgraduate Program in Pharmaceutical Sciences, Federal University of Sergipe, São Cristóvão, Brazil.
Paula Dos Passos MenezesSejaPhD, Brazil.
Luiza Abrahão FrankPostgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Mairim Russo SerafiniPostgraduate Program in Pharmaceutical Sciences, Federal University of Sergipe, São Cristóvão, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flavonoids such as silibinin, hesperetin, and phloretin exhibit well-documented biological activities, including anti-inflammatory, cytoprotective, anticarcinogenic, and antioxidant effects. However, their clinical application remains limited due to challenges such as poor aqueous solubility, low bioavailability, and restricted intestinal absorption, which can significantly reduce their pharmacological efficacy. This review analyzed patents related to innovative pharmaceutical technologies for flavonoids. The analysis used databases from the World Intellectual Property Organization and the European Patent Office. Following a comprehensive screening process, 38 patents were selected for detailed examination. These patents highlighted numerous studies on novel formulations, characterizations, and proprietary conditions. This review highlights technologies, such as nanocapsules, nanoemulsions, solid dispersions, phospholipid carriers, inclusion complexes, microemulsions, and other advanced systems, which enhance bioactive molecules' water solubility and stability. Consequently, these technologies improve permeability and absorption through the intended administration route, demonstrating the potential of flavonoids as promising candidates for various treatments, particularly when integrated into pharmaceutical technologies.

Indexed as

FlavonoidsPatents as TopicTechnology, PharmaceuticalAnimalsHumansSolubilityFlavonoidsflavonoidsHesperetinpatentspharmaceutical technologiesphloretinsilibinin

Identifiers

PMID39835701
PMCPMC11792795

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.